Prognostic value of upar forms in colon and breast cancer

Información del proyecto

TIMO PIIRONEN

Identificador del acuerdo de subvención: QLK4-CT-1999-51464

Proyecto cerrado

Fecha de inicio 1 Agosto 2000

Fecha de finalización 31 Julio 2002

Financiado con arreglo a

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coste total € 143 952,00

Aportación de la UE € 143 952,00

Coordinado por

COPENHAGEN UNIVERSITY HOSPITAL
Denmark

Objetivo

Investigation of the clinical prognostic value of soluble urokinase plasminogen activator receptor (uPAR) forms in blood and tissue extracts from patients with colon and breast cancer, aiming to develop new methods which will aid in the decision-making needed in the management of cancer patients.

Ámbito científico

• medical and health sciences › clinical medicine › oncology › breast cancer

Programa(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Tema(s)

• 1.1.1.-4. - Key action Environment and Health

Convocatoria de propuestas

Data not available

Régimen de financiación

RGI - Research grants (individual fellowships)

Coordinador

COPENHAGEN UNIVERSITY HOSPITAL

• Aportación de la UE: Sin datos
• Dirección: Stransboulevarden 49 ; 2100 KOEPENHAGEN ; Dinamarca
• Coste total: Sin datos